Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, August 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 159 articles:
HTML format


 

Single Articles

  1. ZHU YD, Lu MY
    Increased expression of TNFRSF14 indicates good prognosis and inhibits bladder cancer proliferation by promoting apoptosis.
    Mol Med Rep. 2018 Jul 23. doi: 10.3892/mmr.2018.9306.
    Abstract    

    Abstract available

  2. HUANG Y, Li G, Wang K, Mu Z, et al
    Collagen Type VI Alpha 3 Chain Promotes Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Transforming Growth Factor beta (TGF-beta)/Smad Pathway.
    Med Sci Monit. 2018;24:5346-5354.
    Abstract    

    Abstract available

  3. GUPTE A, Matcha A, Lauzardo M
    Mycobacterium bovis BCG spinal osteomyelitis in a patient with bladder cancer without a history of BCG instillation.
    BMJ Case Rep. 2018;2018.
    Abstract    

    Abstract available

  4. BOSSCHIETER J, Nieuwenhuijzen JA, Vis AN, van Ginkel T, et al
    An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups.
    Urol Oncol. 2018 Jul 28. pii: S1078-1439(18)30195.
    Abstract    

    Abstract available

  5. JAYARAJAH U, Herath KB, Fernando MH, Kuruppu SN, et al
    A clinico-pathological study of non-urothelial bladder cancers in a cohort of patients from a tertiary care urology unit in Sri Lanka
    Ceylon Med J. 2018;63:92-94.
    Abstract    



  6. KIDA K, Shimizu Y, Ogawa K, Kanamaru S, et al
    [Distant Metastasis in Patients with Non-Muscle Invasive Bladder Cancer without Local Recurrence : Report of Two Rare Cases].
    Hinyokika Kiyo. 2018;64:271-275.
    Abstract    

    Abstract available

  7. EL-ARABEY AA
    Correction to: New insight for metformin against bladder cancer.
    Genes Environ. 2018;40:16.
    Abstract    

    Abstract available

  8. STAKISAITIS D, Jukneviciene M, Ulys A, Zaliuniene D, et al
    ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.
    Oncol Lett. 2018;16:1321-1331.
    Abstract    

    Abstract available

  9. BABJUK M, Burger M, Comperat EM, Gontero P, et al
    Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?
    Eur Urol Focus. 2018 Jul 27. pii: S2405-4569(18)30189.
    Abstract    

    Abstract available

  10. KIMURA S, Soria F, D'Andrea D, Foerster B, et al
    Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2018 Jul 6. pii: S1558-7673(18)30415.
    Abstract    

    Abstract available

  11. LI Z, Hong S, Liu Z
    LncRNA LINC00641 predicts prognosis and inhibits bladder cancer progression through miR-197-3p/KLF10/PTEN/PI3K/AKT cascade.
    Biochem Biophys Res Commun. 2018 Jul 27. pii: S0006-291X(18)31622.
    Abstract    

    Abstract available

  12. PATERSON C, Jensen BT, Jensen JB, Nabi G, et al
    Unmet informational and supportive care needs of patients with muscle invasive bladder cancer: A systematic review of the evidence.
    Eur J Oncol Nurs. 2018;35:92-101.
    Abstract    

    Abstract available

  13. BAYRAM D, Armagan I, Ozgocmen M, Senol N, et al
    Determination of Apoptotic Effect of Juglone on Human Bladder Cancer TCC-SUP and RT-4 Cells: An In Vitro Study.
    J Environ Pathol Toxicol Oncol. 2018;37:173-181.
    Abstract    

    Abstract available

  14. QIN Z, Wang Y, Tang J, Zhang L, et al
    High LINC01605 expression predicts poor prognosis and promotes tumor progression via upregulation of MMP9 in bladder cancer.
    Biosci Rep. 2018 Jul 27. pii: BSR20180562. doi: 10.1042/BSR20180562.
    Abstract    

    Abstract available

  15. HUANG Y, Zhou S, He C, Deng J, et al
    Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways.
    Cancer Commun (Lond). 2018;38:50.
    Abstract    

    Abstract available

  16. LIN YC, Chen WJ, Huang CY, Shiue HS, et al
    Corrigendum to "Polymorphisms of Arsenic (+3 Oxidation State) Methyltransferase and Arsenic Methylation Capacity Affect the Risk of Bladder Cancer".
    Toxicol Sci. 2018;164:644.
    Abstract    



  17. SHERIF A
    The long perspective in emergence of neoadjuvant chemotherapy for bladder cancer in Ontario, Canada-space for improvement with regular and organized multidisciplinary team meetings.
    Transl Androl Urol. 2018;7:508-510.
    Abstract    



  18. KOSHKIN VS, Grivas P
    Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research.
    Transl Androl Urol. 2018;7:504-507.
    Abstract    



  19. BAYRAMOV B, Gunes S, Buyukalpelli R, Aydin O, et al
    Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer.
    Onco Targets Ther. 2018;11:4189-4196.
    Abstract    

    Abstract available

  20. DARRIET F, Bernioles P, Loukil A, Saidani N, et al
    Fluorescence in situ hybridization microscopic detection of Bacilli Calmette Guerin mycobacteria in aortic lesions: A case report.
    Medicine (Baltimore). 2018;97:e11321.
    Abstract    

    Abstract available

  21. STIGLIANO A, Lardo P, Cerquetti L, Aschelter AM, et al
    Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.
    Medicine (Baltimore). 2018;97:e10904.
    Abstract    

    Abstract available

  22. NIU Q, Lu Y, Wu Y, Xu S, et al
    The effect of marital status on the survival of patients with bladder urothelial carcinoma: A SEER database analysis.
    Medicine (Baltimore). 2018;97:e11378.
    Abstract    

    Abstract available

  23. YU C, Stefanson O, Liu Y, Wang ZA, et al
    Novel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation.
    J Vis Exp. 2018;.
    Abstract    

    Abstract available

  24. BOLAT D, Gunlusoy B, Aydogdu O, Aydin ME, et al
    Comparing the short - term outcomes and complications of monopolar and bipolar transurethral resection of bladder tumors in patients with coronary artery disese: a prospective, randomized, controlled study.
    Int Braz J Urol. 2018;44:717-725.
    Abstract    

    Abstract available

  25. GARRIDO-ABAD P, Rodriguez-Cabello MA, Gonzalez-Gordaliza C, Vera-Beron R, et al
    BCG instillations can mimic prostate cancer on multiparametric MRI.
    Int Braz J Urol. 2018;44:835-837.
    Abstract    



  26. SAADEH YS, Hollon TC, Fisher-Hubbard A, Savastano LE, et al
    Primary diffuse leptomeningeal melanomatosis: Description and recommendations.
    J Clin Neurosci. 2018;50:139-143.
    Abstract    

    Abstract available

  27. ZATTONI F, Morlacco A, Zattoni F
    Preoperative chronic kidney disease before radical cystectomy as predictor of oncological outcomes: a pick of the iceberg?
    World J Urol. 2018;36:993.
    Abstract    



  28. SALTSMAN JA, Malek MM, Reuter VE, Hammond WJ, et al
    Urothelial neoplasms in pediatric and young adult patients: A large single-center series.
    J Pediatr Surg. 2018;53:306-309.
    Abstract    

    Abstract available

  29. PATRIARCA C, Hurle R, Colombo P, Colecchia M, et al
    In reply to: Lawless et al. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression.
    Histopathology. 2018;72:361-362.
    Abstract    



  30. ROBERTSON AG, Kim J, Al-Ahmadie H, Bellmunt J, et al
    Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.
    Cell. 2018;174:1033.
    Abstract    



  31. WANG XS, Zhao MQ, Zhang L, Kong DJ, et al
    Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer: a meta-analysis.
    Am J Transl Res. 2018;10:1935-1948.
    Abstract    

    Abstract available

  32. GUPTA A, Gupta A, Gupta S, Chauhan U, et al
    Are incidentally detected gall bladder cancers really incidental? A report of two cases from a developing nation.
    Trop Doct. 2018 Aug 8:49475518788486. doi: 10.1177/0049475518788486.
    Abstract    

    Abstract available

  33. SUGIURA S, Noto N, Koizumi M, Takamoto D, et al
    [Post-Operative Immediate Single Instillation of Chemotherapy as Prevention of Recurrence after Transurethral Resection of Intermediate-High Risk Non-Muscle-Invasive Bladder Cancer].
    Hinyokika Kiyo. 2018;64:297-301.
    Abstract    

    Abstract available

  34. ZHANG Q, Chen Z
    Sensitization of cisplatin resistant bladder tumor by combination of cisplatin treatment and co-culture of dendritic cells with apoptotic bladder cancer cells.
    Cell Mol Biol (Noisy-le-grand). 2018;64:102-107.
    Abstract    

    Abstract available

  35. GHATALIA P, Zibelman M, Geynisman DM, Plimack E, et al
    Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
    Ther Adv Med Oncol. 2018;10:1758835918788310.
    Abstract    

    Abstract available

  36. XIE WZ, Jin YH, Leng WD, Wang XH, et al
    Periodontal Disease and Risk of Bladder Cancer: A Meta-Analysis of 298476 Participants.
    Front Physiol. 2018;9:979.
    Abstract    

    Abstract available

  37. PENG L, Shang W, Guo P, He K, et al
    Phage Display-Derived Peptide-based Dual-Modality Imaging Probe for Bladder Cancer Diagnosis and Resection Post-Instillation: A Preclinical Study.
    Mol Cancer Ther. 2018 Aug 6. pii: 1535-7163.MCT-18-0212.
    Abstract    

    Abstract available

  38. SAEMUNDSSON Y, Simoulis A, Liedberg F
    Sanctuary Testicular Bladder Cancer Metastasis 10 Years After Radical Cystectomy and Adjuvant Chemotherapy.
    Clin Genitourin Cancer. 2018 Jul 17. pii: S1558-7673(18)30449.
    Abstract    



  39. CREIGHTON CJ
    The clinical applications of the cancer genome atlas project for bladder cancer.
    Expert Rev Anticancer Ther. 2018 Aug 6. doi: 10.1080/14737140.2018.1508999.
    Abstract    

    Abstract available

  40. ABBAOUI B, Lucas CR, Riedl KM, Clinton SK, et al
    Cruciferous Vegetables, Isothiocyanates and Bladder Cancer Prevention.
    Mol Nutr Food Res. 2018 Aug 5:e1800079. doi: 10.1002/mnfr.201800079.
    Abstract    

    Abstract available

  41. ARAI S, Hara T, Matsui Y, Koido K, et al
    Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer.
    Case Rep Oncol. 2018;11:450-460.
    Abstract    

    Abstract available

  42. WU S, Zheng J, Li Y, Wu Z, et al
    Development and Validation of an MRI-Based Radiomics Signature for the Preoperative Prediction of Lymph Node Metastasis in Bladder Cancer.
    EBioMedicine. 2018 Aug 2. pii: S2352-3964(18)30272.
    Abstract    

    Abstract available

  43. VARTOLOMEI MD, Ferro M, Cantiello F, Lucarelli G, et al
    Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2018 Jul 6. pii: S1558-7673(18)30183.
    Abstract    

    Abstract available

  44. YU C, Longfei L, Long W, Feng Z, et al
    LncRNA PVT1 regulates VEGFC through inhibiting miR-128 in bladder cancer cells.
    J Cell Physiol. 2018 Aug 4. doi: 10.1002/jcp.26929.
    Abstract    

    Abstract available

  45. AHLEN BERGMAN E, Hartana CA, Johansson M, Linton LB, et al
    Increased CD4(+) T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients.
    Clin Epigenetics. 2018;10:102.
    Abstract    

    Abstract available

  46. LI Z, Zhou L, Lin C, Pan X, et al
    MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.
    Life Sci. 2018 Jul 31. pii: S0024-3205(18)30443.
    Abstract    

    Abstract available

  47. BELLMUNT J
    Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.
    Biomedicines. 2018;6.
    Abstract    

    Abstract available

  48. CHEN D, Li SG, Chen JY, Xiao M, et al
    MiR-183 maintains canonical Wnt signaling activity and regulates growth and apoptosis in bladder cancer via targeting AXIN2.
    Eur Rev Med Pharmacol Sci. 2018;22:4828-4836.
    Abstract    

    Abstract available

  49. ALANEE S, Alvarado-Cabrero I, Murugan P, Kumar R, et al
    Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder.
    World J Urol. 2018 Aug 1. pii: 10.1007/s00345-018-2421.
    Abstract    

    Abstract available

  50. SZYMANSKA B, Matuszewski M, Dembowski J, Zdrojowy R, et al
    Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis.
    Biomed Res Int. 2018;2018:8315410.
    Abstract    

    Abstract available

  51. SALMINEN A, Jambor I, Merisaari H, Ettala O, et al
    (11)C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial).
    Cancer Imaging. 2018;18:25.
    Abstract    

    Abstract available

  52. LIN HN, Gu XY, Zhang SW, Zeng HM, et al
    [Analysis on incidence and mean age at diagnosis for Global Cancer].
    Zhonghua Zhong Liu Za Zhi. 2018;40:543-549.
    Abstract    

    Abstract available

  53. JALON-MONZON A, Gonzalez-Ruiz de Leon C, Alvarez-Mugica M, Mendez-Ramirez S, et al
    [Usefulness of cold ureteral biopsy during radical cystectomy as a predictor of recurrence risk: Review of our series.]
    Arch Esp Urol. 2018;71:486-494.
    Abstract    

    Abstract available

  54. SKOWRON MA, Melnikova M, van Roermund JGH, Romano A, et al
    Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  55. HAMILOU Z, Lavaud P, Loriot Y
    Atezolizumab in urothelial bladder carcinoma.
    Future Oncol. 2018;14:331-341.
    Abstract    

    Abstract available

  56. WALTERS L, Martin O, Price J, Sula MM, et al
    Expression of receptor tyrosine kinase targets PDGFR-beta, VEGFR2 and KIT in canine transitional cell carcinoma.
    Vet Comp Oncol. 2018;16:E117-E122.
    Abstract    

    Abstract available

  57. ZHOU Q, Ding W, Weng Y, Ding G, et al
    NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
    Chemotherapy. 2018;63:191-197.
    Abstract    

    Abstract available

  58. SARGOS P, Baumann BC, Eapen L, Christodouleas J, et al
    Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.
    Cancer Treat Rev. 2018;70:88-97.
    Abstract    

    Abstract available

  59. STONE BV, Ayangbesan A, Taylor BL, Golombos DM, et al
    Urinary pH and the risk of recurrence in patients with non-muscle invasive bladder cancer.
    Can J Urol. 2018;25:9407-9412.
    Abstract    

    Abstract available

  60. DING M, Zhan H, Liao X, Li A, et al
    Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer.
    Int J Biol Sci. 2018;14:1268-1276.
    Abstract    

    Abstract available

  61. YE Z, Chen J, Hong Y, Xin W, et al
    The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guerin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis.
    Onco Targets Ther. 2018;11:4641-4649.
    Abstract    

    Abstract available

  62. WANG HR, Zhang WY, Liu XH, Hu H, et al
    [Clinical application of partial cystectomy with augmentation cystoplasty for invasive bladder cancer in elderly patients].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2018;50:626-629.
    Abstract    

    Abstract available

  63. ZHOU JH, Wang D, Wang HR, Hou XL, et al
    [Cytotoxic effects of gammadeltaT cells on bladder cancer cells and expression of MICA/B in bladder cancer].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2018;50:595-601.
    Abstract    

    Abstract available

  64. CHAKRAVARTHI BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, et al
    A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.
    Neoplasia. 2018;20:894-904.
    Abstract    

    Abstract available

  65. POLAT F, Yilmaz M, Budak Diler S
    The Association of MYNN and TERC Gene Polymorphisms and Bladder Cancer in a Turkish Population.
    Urol J. 2018 Aug 14. pii: 4083/1263.
    Abstract    

    Abstract available

  66. DALKILIC A, Bayar G, Kilinc MF
    A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.
    Urol J. 2018 Aug 14. pii: 4091/1262.
    Abstract    

    Abstract available

  67. CROZIER J, Papa N, Perera M, Ngo B, et al
    Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis.
    World J Urol. 2018 Aug 17. pii: 10.1007/s00345-018-2439.
    Abstract    

    Abstract available

  68. JALLAD S, Thomas P, Newport MJ, Kern F, et al
    Baseline cytokine profiles of tuberculin-specific CD4+ T-cells in non-muscle invasive bladder cancer may predict outcomes of BCG immunotherapy.
    Cancer Immunol Res. 2018 Aug 17. pii: 2326-6066.CIR-18-0046.
    Abstract    

    Abstract available

  69. YANG Y, Zhang LJ, Bai XG, Xu HJ, et al
    Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
    Biomed Pharmacother. 2018;106:1307-1316.
    Abstract    

    Abstract available

  70. HUA X, Xu J, Deng X, Xu J, et al
    New Compound ChlA-F Induces Autophagy-dependent Anti-cancer Effect via Upregulating Sestrin-2 in Human Bladder Cancer.
    Cancer Lett. 2018 Aug 14. pii: S0304-3835(18)30525.
    Abstract    

    Abstract available

  71. PEARCE S, Daneshmand S
    Enhanced Endoscopy in Bladder Cancer.
    Curr Urol Rep. 2018;19:84.
    Abstract    

    Abstract available

  72. WANG L, Zhao J, Yang C, Kuang R, et al
    Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.
    Cell Physiol Biochem. 2018;48:2364-2373.
    Abstract    

    Abstract available

  73. MESSING EM
    Financial Toxicity of Having Bladder Cancer.
    Bladder Cancer. 2018;4:351-352.
    Abstract    



  74. BLACK PC, Goebell PJ, Kamat AM, Nawroth R, et al
    New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017.
    Bladder Cancer. 2018;4:339-342.
    Abstract    



  75. JAKOBSSON L, Chebil G, Marzouka NA, Liedberg F, et al
    Low Frequency of Intratumor Heterogeneity in Bladder Cancer Tissue Microarrays.
    Bladder Cancer. 2018;4:327-337.
    Abstract    

    Abstract available

  76. VARTOLOMEI L, Ferro M, Mirone V, Shariat SF, et al
    Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients.
    Bladder Cancer. 2018;4:319-326.
    Abstract    

    Abstract available

  77. JOCHEMS SHJ, van Osch FHM, Reulen RC, van Hensbergen M, et al
    Total Fluid Intake and the Risk of Recurrence in Patients With Non-Muscle Invasive Bladder Cancer: A Prospective Cohort Study.
    Bladder Cancer. 2018;4:303-310.
    Abstract    

    Abstract available

  78. KARSH L, Shore N, Soloway M, Bhat G, et al
    Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2018;4:293-301.
    Abstract    

    Abstract available

  79. GOODSPEED A, Jean A, Theodorescu D, Costello JC, et al
    A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition.
    Bladder Cancer. 2018;4:269-282.
    Abstract    

    Abstract available

  80. VLACHOSTERGIOS PJ, Jakubowski CD, Niaz MJ, Lee A, et al
    Antibody-Drug Conjugates in Bladder Cancer.
    Bladder Cancer. 2018;4:247-259.
    Abstract    

    Abstract available

  81. TSAI CH, Chen YT, Chang YH, Hsueh C, et al
    Systematic verification of bladder cancer-associated tissue protein biomarker candidates in clinical urine specimens.
    Oncotarget. 2018;9:30731-30747.
    Abstract    

    Abstract available

  82. MONTEIRO LL, Witjes JA, Agarwal PK, Anderson CB, et al
    ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    World J Urol. 2018 Aug 14. pii: 10.1007/s00345-018-2438.
    Abstract    

    Abstract available

  83. MATULAY JT, Kamat AM
    Advances in risk stratification of bladder cancer to guide personalized medicine.
    F1000Res. 2018;7.
    Abstract    

    Abstract available

  84. BUCEVIC POPOVIC V, Situm M, Chow CT, Chan LS, et al
    The urinary microbiome associated with bladder cancer.
    Sci Rep. 2018;8:12157.
    Abstract    

    Abstract available

  85. LI H, Chen W, Ma J, Zang R, et al
    Involved-field irradiation for elderly bladder cancer patients.
    Curr Probl Cancer. 2018 Aug 4. pii: S0147-0272(18)30188.
    Abstract    

    Abstract available

  86. HURST C, Rosenberg J, Knowles M
    SnapShot: Bladder Cancer.
    Cancer Cell. 2018;34:350-350.
    Abstract    

    Abstract available

  87. ZHAO Q, Gao S, Du Q, Liu Y, et al
    Long non-coding RNA SNHG20 promotes bladder cancer via activating the Wnt/beta-catenin signalling pathway.
    Int J Mol Med. 2018 Aug 10. doi: 10.3892/ijmm.2018.3819.
    Abstract    

    Abstract available

  88. FERNANDEZ MI, Brausi M, Clark PE, Cookson MS, et al
    Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.
    World J Urol. 2018 Aug 13. pii: 10.1007/s00345-018-2436.
    Abstract    

    Abstract available

  89. SHAIKHET L, Bunimovich-Mendrazitsky S
    Stability Analysis of Delayed Immune Response BCG Infection in Bladder Cancer Treatment Model by Stochastic Perturbations.
    Comput Math Methods Med. 2018;2018:9653873.
    Abstract    

    Abstract available

  90. XUE Y, Yang L, Li J, Yan Y, et al
    Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFkappaB signaling pathway.
    Onco Targets Ther. 2018;11:4413-4429.
    Abstract    

    Abstract available

  91. PERERA M, McGrath S, Sengupta S, Crozier J, et al
    Pelvic lymph node dissection during radical cystectomy for muscle-invasive bladder cancer.
    Nat Rev Urol. 2018 Aug 13. pii: 10.1038/s41585-018-0066.
    Abstract    

    Abstract available

  92. LI X, Tian Z, Jin H, Xu J, et al
    Decreased c-Myc mRNA Stability via miR-141-3p/AUF1 Axis Is Crucial for p63alpha Inhibition of Cyclin D1 Transcription and Bladder Cancer Cell Tumorigenicity.
    Mol Cell Biol. 2018 Aug 13. pii: MCB.00273-18. doi: 10.1128/MCB.00273.
    Abstract    

    Abstract available

  93. MIYATA Y, Matsuo T, Araki K, Nakamura Y, et al
    Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer.
    Medicines (Basel). 2018;5.
    Abstract    

    Abstract available

  94. BRAVI F, Spei ME, Polesel J, Di Maso M, et al
    Mediterranean Diet and Bladder Cancer Risk in Italy.
    Nutrients. 2018;10.
    Abstract    

    Abstract available

  95. BI J, Liu H, Cai Z, Dong W, et al
    Circ-BPTF promotes bladder cancer progression and recurrence through the miR-31-5p/RAB27A axis.
    Aging (Albany NY). 2018 Aug 9. pii: 101520. doi: 10.18632/aging.101520.
    Abstract    

    Abstract available

  96. MOUW KW
    Towards biomarker-informed trimodality therapy (TMT) approaches for muscle-invasive bladder cancer.
    Int J Radiat Oncol Biol Phys. 2018 Aug 10. pii: S0360-3016(18)33521.
    Abstract    



  97. LI J, Qiu M, An Y, Huang J, et al
    miR-7-5p acts as a tumor suppressor in bladder cancer by regulating the hedgehog pathway factor Gli3.
    Biochem Biophys Res Commun. 2018 Aug 9. pii: S0006-291X(18)31670.
    Abstract    

    Abstract available

  98. GILFRICH C, Maurer O, Spachmann PJ, Dombrowski MK, et al
    Wake-up call for more doctor-patient communication and an increase in public information campaigns on the risk factor of smoking with regard to the development and prognosis of bladder cancer.
    World J Urol. 2018 Aug 11. pii: 10.1007/s00345-018-2435.
    Abstract    



  99. ALAMEDDINE M, Kineish O, Ritch C
    Predicting Response to Intravesical Therapy in Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2018 Aug 8. pii: S2405-4569(18)30216.
    Abstract    

    Abstract available

  100. HUANG W, Lu Y, Wang F, Huang X, et al
    Downregulation of circular RNA hsa_circ_0000144 inhibits bladder cancer progression via stimulating miR-217 and suppressing RUNX2 expression.
    Gene. 2018 Aug 8. pii: S0378-1119(18)30897-7. doi: 10.1016/j.gene.2018.
    Abstract    

    Abstract available

  101. MOHAMMED B, Paul OJ, Mustapha A, Soufiane M, et al
    [Bladder exstrophy with adenocarcinoma in an adult patient: a case report].
    Pan Afr Med J. 2018;29:197.
    Abstract    

    Abstract available

  102. ZHOU R, Zang G, Yu Q, Pang K, et al
    Transurethral fluorescence cystoscopy guidance for total resection of bladder tumor.
    J Biol Regul Homeost Agents. 2018;32:669-672.
    Abstract    

    Abstract available

  103. MACRI F, Di Pietro S, Mangano C, Pugliese M, et al
    Quantitative evaluation of canine urinary bladder transitional cell carcinoma using contrast-enhanced ultrasonography.
    BMC Vet Res. 2018;14:84.
    Abstract    

    Abstract available

  104. INOUE S, Ide H, Fujita K, Mizushima T, et al
    Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract.
    Int J Mol Sci. 2018;19.
    Abstract    

    Abstract available

  105. KATSILA T, Liontos M, Patrinos GP, Bamias A, et al
    The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment.
    EBioMedicine. 2018;28:43-50.
    Abstract    

    Abstract available

  106. LI Z, Wang KE, Zhou XL, Zhou J, et al
    Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder.
    Med Sci Monit. 2018;24:438-447.
    Abstract    

    Abstract available

  107. WEI X, Lu J, Siddiqui KM, Li F, et al
    Does previous abdominal surgery adversely affect perioperative and oncologic outcomes of laparoscopic radical cystectomy?
    World J Surg Oncol. 2018;16:10.
    Abstract    

    Abstract available

  108. LI YP, Zhu JF, Huang KT, Wang RR, et al
    Reduction of Tat-interacting Protein 30 Expression Could be a Prognostic Marker in Bladder Urothelial Cancer.
    Chin Med J (Engl). 2018;131:188-193.
    Abstract    

    Abstract available

  109. WANG X, Liu Y, Liu W, Zhang Y, et al
    Ubenimex, an APN inhibitor, could serve as an antitumor drug in RT112 and 5637 cells by operating in an Aktassociated manner.
    Mol Med Rep. 2018;17:4531-4539.
    Abstract    

    Abstract available

  110. WIECZOREK E, Reszka E
    mRNA, microRNA and lncRNA as novel bladder tumor markers.
    Clin Chim Acta. 2018;477:141-153.
    Abstract    

    Abstract available

  111. DAVALOS L, Kushlaf H
    New onset of seropositive generalized myasthenia gravis following intravesical Bacille Calmette-Guerin treatment for bladder cancer: A case study.
    Muscle Nerve. 2018 Aug 25. doi: 10.1002/mus.26328.
    Abstract    



  112. TANG Y, Cong X, Wang S, Fang S, et al
    GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through beta1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
    Biochem Biophys Res Commun. 2018 Aug 21. pii: S0006-291X(18)31790.
    Abstract    

    Abstract available

  113. BI Y, Chen S, Jiang J, Yao J, et al
    CDCA8 expression and its clinical relevance in patients with bladder cancer.
    Medicine (Baltimore). 2018;97:e11899.
    Abstract    

    Abstract available

  114. KOIE T, Ohyama C, Yoneyama T, Nagasaka H, et al
    Robotic cross-folded U-configuration intracorporeal ileal neobladder for muscle-invasive bladder cancer: Initial experience and functional outcomes.
    Int J Med Robot. 2018 Aug 23:e1955. doi: 10.1002/rcs.1955.
    Abstract    

    Abstract available

  115. MIKI M, Ishii K, Sasaki T, Kato M, et al
    Predicting the tumorigenic phenotype of human bladder cancer cells by combining with fetal rat mesenchyme.
    Urol Oncol. 2018 Aug 20. pii: S1078-1439(18)30263.
    Abstract    

    Abstract available

  116. GILD P, Wankowicz SA, Sood A, von Landenberg N, et al
    Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.
    Urol Oncol. 2018 Aug 20. pii: S1078-1439(18)30267.
    Abstract    

    Abstract available

  117. LIU B, Domes T, Jana K
    Evaluation of an enhanced recovery protocol on patients having radical cystectomy for bladder cancer.
    Can Urol Assoc J. 2018 Jul 31. pii: cuaj.5273. doi: 10.5489/cuaj.5273.
    Abstract    

    Abstract available

  118. LI J, Ying Y, Xie H, Jin K, et al
    Dual regulatory role of CCNA2 in modulating CDK6 and MET-mediated cell-cycle pathway and EMT progression is blocked by miR-381-3p in bladder cancer.
    FASEB J. 2018 Aug 23:fj201800667R. doi: 10.1096/fj.201800667.
    Abstract    

    Abstract available

  119. WU Z, Huang W, Wang X, Wang T, et al
    Circular RNA CEP128 acts as a sponge of miR-145-5p in promoting the bladder cancer progression via regulating SOX11.
    Mol Med. 2018;24:40.
    Abstract    

    Abstract available

  120. FENG F, Chen A, Huang J, Xia Q, et al
    Long noncoding RNA SNHG16 contributes to the development of bladder cancer via regulating miR-98/STAT3/Wnt/beta-catenin pathway axis.
    J Cell Biochem. 2018 Aug 21. doi: 10.1002/jcb.27257.
    Abstract    

    Abstract available

  121. WANG Y, Chang Q, Li Y
    Racial differences in Urinary Bladder Cancer in the United States.
    Sci Rep. 2018;8:12521.
    Abstract    

    Abstract available

  122. WADA K, Tsuji M, Tamura T, Konishi K, et al
    Soy isoflavone intake and bladder cancer risk in Japan: From the Takayama study.
    Cancer Epidemiol Biomarkers Prev. 2018 Aug 21. pii: 1055-9965.EPI-18-0283.
    Abstract    

    Abstract available

  123. WU CT, Lin WY, Chen WC, Chen MF, et al
    Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
    Ann Surg Oncol. 2018 Aug 20. pii: 10.1245/s10434-018-6706.
    Abstract    

    Abstract available

  124. MCCONKEY DJ, Choi W
    Molecular Subtypes of Bladder Cancer.
    Curr Oncol Rep. 2018;20:77.
    Abstract    

    Abstract available

  125. GUO L, Yin M, Wang Y
    CREB1, a direct target of miR-122, promotes cell proliferation and invasion in bladder cancer.
    Oncol Lett. 2018;16:3842-3848.
    Abstract    

    Abstract available

  126. LU P, Cui J, Chen K, Lu Q, et al
    Diagnostic accuracy of the UBC((R)) Rapid Test for bladder cancer: A meta-analysis.
    Oncol Lett. 2018;16:3770-3778.
    Abstract    

    Abstract available

  127. LI T, Xu K, Liu Y
    Anticancer effect of salidroside reduces viability through autophagy/PI3K/Akt and MMP-9 signaling pathways in human bladder cancer cells.
    Oncol Lett. 2018;16:3162-3168.
    Abstract    

    Abstract available

  128. SYRING I, Weiten R, Muller T, Schmidt D, et al
    The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy.
    Oncol Lett. 2018;16:3013-3021.
    Abstract    

    Abstract available

  129. XIU W, Ma J, Lei T, Zhang M, et al
    AG490 reverses phenotypic alteration of dendritic cells by bladder cancer cells.
    Oncol Lett. 2018;16:2851-2856.
    Abstract    

    Abstract available

  130. GOPALAKRISHNA A, Chang A, Longo TA, Fantony JJ, et al
    Dietary patterns and health-related quality of life in bladder cancer survivors.
    Urol Oncol. 2018 Aug 17. pii: S1078-1439(18)30200.
    Abstract    

    Abstract available

  131. WHONGSIRI P, Pimratana C, Wijitsettakul U, Jindatip D, et al
    LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression.
    Cancer Genomics Proteomics. 2018;15:143-151.
    Abstract    

    Abstract available

  132. ABOUSHOUSHA T, Hammam O, Helal N, El Dahshan S, et al
    Impact of Cyclin D1 and Heterogeneous Nuclear Ribonucleoprotein-K (HnRNP-K) on Urinary Bladder Carcinogenesis
    Asian Pac J Cancer Prev. 2018;19:513-519.
    Abstract    

    Abstract available

  133. FELDMAN A, Borak S, Rais-Bahrami S, Gordetsky J, et al
    Secondary Malignancies of the Bladder: Avoiding the Diagnostic Pitfall.
    Int J Surg Pathol. 2018;26:120-125.
    Abstract    

    Abstract available

  134. COOPER CT, Greene BD, Fegan JE, Rovira D, et al
    External beam radiation therapy for amyloidosis of the urinary bladder.
    Pract Radiat Oncol. 2018;8:25-27.
    Abstract    



  135. HARRI PA, Alexander L, Camacho JC, Moreno CC, et al
    Magnetic Resonance Imaging Evaluation of Urothelial Cell Carcinoma: Histopathological Correlation, Staging, and Treatment Planning.
    Curr Probl Diagn Radiol. 2018;47:28-41.
    Abstract    



  136. NAKAMURA R, Kakuhara H, Kikuchi K, Segawa T, et al
    Partial Bladder Boost Using Lipiodol Marking During Image-guided Radiotherapy for Bladder Cancer.
    Anticancer Res. 2018;38:4827-4831.
    Abstract    

    Abstract available

  137. TSAI KW, Kuo WT, Jeng SY
    Tight Junction Protein 1 Dysfunction Contributes to Cell Motility in Bladder Cancer.
    Anticancer Res. 2018;38:4607-4615.
    Abstract    

    Abstract available

  138. GOUSSIA AC, Papoudou-Bai A, Charchanti A, Kitsoulis P, et al
    Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas.
    Anticancer Res. 2018;38:3985-3988.
    Abstract    

    Abstract available

  139. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    Diagnostic Utility of Prostein, Uroplakin II and SATB2 for Diagnosing Carcinoma of Unknown Primary Origin: A Systematic Immunohistochemical Profiling.
    Anticancer Res. 2018;38:4759-4766.
    Abstract    

    Abstract available

  140. HEIJNSDIJK EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, et al
    Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.
    BJU Int. 2018 Aug 1. doi: 10.1111/bju.14502.
    Abstract    

    Abstract available

  141. LANE G, Risk M, Fan Y, Krishna S, et al
    Persistent muscle invasive bladder cancer after neoadjuvant chemotherapy: An analysis of SEER-Medicare data.
    BJU Int. 2018 Aug 20. doi: 10.1111/bju.14529.
    Abstract    

    Abstract available

  142. BREYER J, Wirtz RM, Erben P, Rinaldetti S, et al
    FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer (NMIBC).
    BJU Int. 2018 Aug 18. doi: 10.1111/bju.14525.
    Abstract    

    Abstract available

  143. ALLIONE A, Pardini B, Viberti C, Giribaldi G, et al
    MMP23B expression and protein levels in blood and urine are associated with bladder cancer.
    Carcinogenesis. 2018 Jul 20. pii: 5056806. doi: 10.1093.
    Abstract    

    Abstract available

  144. RAJA R, Kuziora M, Brohawn P, Higgs BW, et al
    Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0386.
    Abstract    

    Abstract available

  145. SCHRAML J, Silva JDC, Babjuk M
    Current concept of transurethral resection of bladder cancer: from re-transurethral resection of bladder cancer to en-bloc resection.
    Curr Opin Urol. 2018 Aug 9. doi: 10.1097/MOU.0000000000000542.
    Abstract    

    Abstract available

  146. DYRSKJOT L, Ingersoll MA
    Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology.
    Curr Opin Urol. 2018 Aug 21. doi: 10.1097/MOU.0000000000000543.
    Abstract    

    Abstract available

  147. GIANNARINI G, Crestani A, Ficarra V
    Re: Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy in Patients with Bladder Cancer (RAZOR): An Open-label, Randomised, Phase 3, Non-inferiority Trial.
    Eur Urol. 2018 Aug 20. pii: S0302-2838(18)30564.
    Abstract    



  148. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    Abstract    



  149. CHEN X, Xu Z, Zhu Z, Chen A, et al
    Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro.
    Int J Oncol. 2018 Jul 25. doi: 10.3892/ijo.2018.4501.
    Abstract    

    Abstract available

  150. CAO J, Wang Q, Wu G, Li S, et al
    miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.
    Int Urol Nephrol. 2018 Aug 16. pii: 10.1007/s11255-018-1959.
    Abstract    

    Abstract available

  151. JURI H, Koyama M, Azuma H, Narumi Y, et al
    Are there any metastases to the chest in non-muscle-invasive bladder cancer patients on follow-up computed tomography?
    Int Urol Nephrol. 2018 Aug 16. pii: 10.1007/s11255-018-1952.
    Abstract    

    Abstract available

  152. GAO F, Wang X, Chen S, Xu T, et al
    CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
    Oncol Rep. 2018 Aug 10. doi: 10.3892/or.2018.6641.
    Abstract    

    Abstract available

  153. XU ZL, Zhang Y, Wang L, Li F, et al
    B7H3 promotes malignant progression of muscleinvasive bladder cancer.
    Oncol Rep. 2018 Aug 17. doi: 10.3892/or.2018.6655.
    Abstract    

    Abstract available

  154. MARI A, D'Andrea D, Kimura S, Resch I, et al
    Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
    Urol Int. 2018;101:1-4.
    Abstract    

    Abstract available

  155. TAN P, Xie N, Yang L, Liu L, et al
    Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Increased the Risk of Intravesical Recurrence.
    Urol Int. 2018;100:92-99.
    Abstract    

    Abstract available

  156. HAN DS, Zhou W, Seigne JD, Lynch KE, et al
    Geographic Variation in Cystoscopy Rates for Suspected Bladder Cancer between Female and Male Medicare Beneficiaries.
    Urology. 2018 Aug 20. pii: S0090-4295(18)30835.
    Abstract    

    Abstract available

  157. DHAWAN D, Hahn NM, Ramos-Vara JA, Knapp DW, et al
    Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.
    PLoS Genet. 2018;14:e1007571.
    Abstract    

    Abstract available

  158. SUTTON AJ, Lamont JV, Evans RM, Williamson K, et al
    An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer.
    PLoS One. 2018;13:e0202796.
    Abstract    

    Abstract available

  159. GARCZYK S, Schneider U, Lurje I, Becker K, et al
    ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    PLoS One. 2018;13:e0202965.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;